ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION

A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE

A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation

A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage

A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

METHOD OF EXTENDING HALF-LIFE OF CRYSTALINE ANTIBODIES

A composition for extending the half-life of a crystalline antibody, including synergistically effective amounts of a half-life-extending compound and a crystalline antibody. A composition for extending the half-life of a crystalline antibody including synergistically effective amounts of lactulose and a crystalline anti-PCSK9 antibody. A method of extending the half-life of a crystalline antibody, by administering a synergistically effective amount of a half-life-extending compound and a crystalline antibody to an individual, and extending the half-life of the crystalline antibody. A method of promoting antibody recycling by affecting a receptor for an antibody to recycle the antibody. 1. A composition for extending the half-life of a crystalline antibody , comprising synergistically effective amounts of a half-life-extending compound and a crystalline antibody.2. The composition of claim 1 , wherein said half-life-extending compound is chosen from the group consisting of a non-absorbable sugar claim 1 , a compound that converts NH3 to NH4+ claim 1 , a prebiotic claim 1 , a hydrogen-generating compound claim 1 , and combinations thereof.3. The composition of claim 2 , wherein said half-life-extending compound is lactulose or homologues thereof and is in an amount lower than indicated for treating constipation claim 2 , said amount being less than 10 g/day.4. The composition of claim 2 , wherein said non-absorbable sugar is chosen from the group consisting of lactulose claim 2 , glucose claim 2 , galactose claim 2 , fructose claim 2 , mannitol claim 2 , inulin claim 2 , sucralose claim 2 , aspartame claim 2 , dextrose claim 2 , maltodextrin claim 2 , homologues claim 2 , and combinations thereof.5. The composition of claim 2 , wherein said prebiotic is chosen from the group consisting of lactulose claim 2 , disaccharides claim 2 , inulin claim 2 , fructooligosaccharides (FOS) claim 2 , xylooligosaccharides (XOS) claim 2 , polydextrose claim 2 , oligofructose- ...

Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation

A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE

A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody. A composition for treating cardiovascular disease including the glycocalyx restoring and maintaining compound and a MAb anti-PCSK9. 1. A composition for treating multiple disease causes comprising a glycocalyx restoring and maintaining compound.4. The composition of claim 1 , wherein said composition is in an oral dosage form.5. The composition of claim 1 , wherein each compound is present in an amount from 5 mg to 750 mg.6. The composition of claim 5 , wherein each compound is present in an amount of 50 mg.7. A method of treating multiple disease causes claim 5 , including the steps of:administering a glycocalyx restoring and maintaining compound to an individual;restoring the glycocalyx;reversing inflammation; andreversing oxidative damage.10. The method of claim 7 , wherein said restoring the glycocalyx step is further defined as restoring the balance of enzymes chosen from the group consisting of antioxidant superoxide dismutase (SOD) claim 7 , anti-inflammatory antithrombin (AT-III) claim 7 , thrombin claim 7 , plasmin claim 7 , protease-3 claim 7 , elastase claim 7 , and ...

Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation

A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome. 1. A method of eliminating a risk of John Cunningham virus (JCV) activation in a subject undergoing immunosuppressive therapy , including the steps of:administering, to a subject latently infected with JCV, an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome;cleaving the target sequence in the JCV genome;disrupting the JCV genome;eliminating the JCV infection;eliminating the risk of JCV activation; andtreating the subject with an immunosuppressive therapy at a time chosen from the group consisting of before, during, or after administering the gene editing composition.2. The method according to claim 1 , additionally including claim 1 , prior to said administering step claim 1 , the steps of screening the subject for latent JCV infection claim 1 , and verifying the presence of a latent JCV infection.3. The method according to claim 1 , wherein the gene editing composition is ...

SMART DOSING FOR CANCER THERAPY

A method of dosing cancer therapies, by collecting patient data including cancer therapies/drugs to be taken, analyzing the data in view of dosing criteria established based on outside data, and determining a dose for each cancer therapy/drug taken. A logic engine for dosing cancer therapies, including an algorithm stored on non-transitory computer readable media for collecting clinical trial data to establish criteria for dosing cancer therapies/drugs to a single patient and patient data and storing the clinical trial data and patient data in a database, analyzing the patient data in view of criteria established from the clinical trial data, and determining a dose for each cancer therapy/drug. A method of adjusting treatment of a cancer patient. 1. A method of dosing cancer therapies , including the steps of:collecting patient data including cancer therapies and drugs to be taken;analyzing the data in view of dosing criteria established based on outside data; anddetermining a dose for each cancer therapy and drug taken.2. The method of claim 1 , wherein said collecting step includes inputting data from a site chosen from the group consisting of clinics claim 1 , electronic medical records (EMRs) claim 1 , pharmaceutical companies claim 1 , private databases claim 1 , and CROs to a central artificial intelligence (AI) claim 1 , and inputting data from monitors claim 1 , EMRs claim 1 , and insurance information to the central AI.3. The method of claim 1 , wherein said collecting step is further defined as collecting data on symptoms claim 1 , diagnoses claim 1 , proposed cancer therapies claim 1 , drugs claim 1 , or treatments claim 1 , fixed demographics claim 1 , temporal values claim 1 , genetic components claim 1 , imaging claim 1 , and unstructured data.4. The method of claim 1 , wherein said analyzing step includes analyzing data relating to pharmacokinetics claim 1 , distribution claim 1 , prior toxicity and efficacy determinations claim 1 , age claim 1 , ...

GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome. 1. A method of eliminating a risk of John Cunningham virus (JCV) activation in a subject undergoing immunosuppressive therapy , including the steps of:administering, to a subject latently infected with JCV, an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome;cleaving the target sequence in the JCV genome;disrupting the JCV genome;eliminating the JCV infection;eliminating the risk of JCV activation; andtreating the subject with an immunosuppressive therapy at a time chosen from the group consisting of before, during, or after administering the gene editing composition.2. The method according to claim 1 , additionally including claim 1 , prior to said administering step claim 1 , the steps of screening the subject for latent JCV infection claim 1 , and verifying the presence of a latent JCV infection.3. The method according to claim 1 , wherein the gene editing composition is ...

CHOLESTEROL-LOWERING COMPOUNDS IN COMBINATION WITH LIPID METABOLISM-ALTERING COMPOUNDS OF NON-ABSORBABLE SUGARS, COMPOUNDS THAT CONVERT NH3 TO NH4+, OR HYDROGEN-GENERATING COMPOUNDS FOR THE TREATMENT OF HIGH CHOLESTEROL AND INFLAMMATION

A composition for treating high cholesterol, including synergistically effective amounts of a cholesterol-lowering agent and a lipid metabolism-altering compound chosen from a non-absorbable sugar, a compound that converts NH3 to NH4+, a hydrogen-generating compound, and combinations thereof. A composition for treating high cholesterol, including synergistically effective amounts of a statin chosen from atorvastatin, cerivastatin, fluvastain, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and lactulose. A method of lowering cholesterol by administering a synergistically effective amount of the composition to an individual, and lowering cholesterol in the individual. 1. A composition for treating high cholesterol , comprising synergistically effective amounts of a cholesterol-lowering agent and a lipid metabolism-altering compound chosen from the group consisting of a non-absorbable sugar , a compound that converts NH3 to NH4+ , hydrogen-generating compound , and combinations thereof.2. The composition of claim 1 , wherein said cholesterol-lowering agent is a statin chosen from the group consisting of atorvastatin claim 1 , cerivastatin claim 1 , fluvastain claim 1 , lovastatin claim 1 , mevastatin claim 1 , pitavastatin claim 1 , pravastatin claim 1 , rosuvastatin claim 1 , and simvastatin.3. The composition of claim 2 , wherein said statin is administered in an amount of 10 to 80 mg/day.4. The composition of claim 1 , wherein said cholesterol-lowering agent is a lipid-lowering antibody.5. The composition of claim 4 , wherein said lipid-lowering antibody is anti-PCSK9 MAb.6. The composition of claim 1 , wherein said lipid metabolism-altering compound is lactulose or homologues thereof and is in an amount of 40 mL to 1000 mL per day.7. The composition of claim 1 , wherein said non-absorbable sugar is chosen from the group consisting of lactulose claim 1 , glucose claim 1 , galactose claim 1 , fructose claim 1 , mannitol claim 1 , ...

Smart dosing for cancer therapy

An application for tracking cancer therapy symptom triggers stored on non-transitory computer readable media including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking triggers of symptoms in cancer patients, by a user inputting data about nutrition, medication, lifestyle, symptoms due to cancer therapy, pain, and user defined metrics in an application stored on non-transitory computer readable media, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's symptoms due to cancer therapy. A method of adjusting treatment of a cancer patient.

Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.

Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, or at least one argonaute protein, which target at least one nucleotide sequence of the JCV genome.

The nip3 family of proteins

There is provided an isolated and purified BNIP3 protein. There is also provided a method for inducing necrosis in cells by transfecting a cell with a BNIP3 protein. A method for inducing necrosis in cells by creating a transgene overexpressing the gene for the BNIP3 protein is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a BNIP3 protein selected from the group consisting essentially of Seq. ID 1 and 2. Also provided is a vector for use in treating disease including BNIP3 or DN NIP and a promoter. A gene therapy having DNA encoding BNIP3 or DN NIP and a promoter, whereby said gene therapy is used to induce necrosis or inhibit necrosis is also provided.

Controlling effects after 5ht2a agonists administration

A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug.

The nip3 family of proteins

There is provided an isolated and purified BNIP3 protein. There is also provided a method for inducing necrosis in cells by transfecting a cell with a BNIP3 protein. A method for inducing necrosis in cells by creating a transgene overexpressing the gene for the BNIP3 protein is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a BNIP3 protein selected from the group consisting essentially of Seq. ID 1 and 2. Also provided is a vector for use in treating disease including BNIP3 or DN NIP and a promoter. A gene therapy having DNA encoding BNIP3 or DN NIP and a promoter, whereby said gene therapy is used to induce necrosis or inhibit necrosis is also provided.

The nip3 family of proteins

There is provided an isolated and purified BNIP3 protein. There is also provided a method for inducing necrosis in cells by transfecting a cell with a BNIP3 protein. A method for inducing necrosis in cells by creating a transgene overexpressing the gene for the BNIP3 protein is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a BNIP3 protein selected from the group consisting essentially of Seq. ID 1 and 2. Also provided is a vector for use in treating disease including BNIP3 or DN NIP and a promoter. A gene therapy having DNA encoding BNIP3 or DN NIP and a promoter, whereby said gene therapy is used to induce necrosis or inhibit necrosis is also provided.

Application for tracking progression and isolating causes of adverse medical conditions

An application for tracking disease, pain, and mental health symptom triggers including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user, wherein the output module provides notice that it is likely that disease or mental health symptoms will appear. A method of preventing the onset of disease or mental health symptoms, by a user inputting data about nutrition, medication, lifestyle, symptoms, and user defined metrics in an application, performing an analysis on the data, outputting a result from the data identifying daily activities that effect the user's disease/mental health and trigger symptoms, including strongest trends, key performance indicators, and tracking over time, and outputting notice that it is likely that disease or mental health symptoms will appear.

Smart dosing for microbiome health

An application for tracking symptom triggers affecting the microbiome stored on non-transitory computer readable media including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking triggers of symptoms affecting the microbiome in a user, by a user inputting data about nutrition, medication, lifestyle, symptoms due to cancer therapy, pain, and user defined metrics in an application stored on non-transitory computer readable media, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's symptoms and microbiome. A method of adjusting treatment of the microbiome of a patient.

Smart dosing for cancer therapy

A method of dosing cancer therapies, by collecting patient data including cancer therapies/drugs to be taken, analyzing the data in view of dosing criteria established based on outside data, and determining a dose for each cancer therapy/drug taken. A logic engine for dosing cancer therapies, including an algorithm stored on non-transitory computer readable media for collecting clinical trial data to establish criteria for dosing cancer therapies/drugs to a single patient and patient data and storing the clinical trial data and patient data in a database, analyzing the patient data in view of criteria established from the clinical trial data, and determining a dose for each cancer therapy/drug. A method of adjusting treatment of a cancer patient.

Smart dosing for microbiome health

An application for tracking symptom triggers affecting the microbiome stored on non-transitory computer readable media including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking triggers of symptoms affecting the microbiome in a user, by a user inputting data about nutrition, medication, lifestyle, symptoms due to cancer therapy, pain, and user defined metrics in an application stored on non-transitory computer readable media, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's symptoms and microbiome. A method of adjusting treatment of the microbiome of a patient.

The nip3 family of proteins

Smart dosing for cancer therapy

A method of dosing cancer therapies, by collecting patient data including cancer therapies/drugs to be taken, analyzing the data in view of dosing criteria established based on outside data, and determining a dose for each cancer therapy/drug taken. A logic engine for dosing cancer therapies, including an algorithm stored on non-transitory computer readable media for collecting clinical trial data to establish criteria for dosing cancer therapies/drugs to a single patient and patient data and storing the clinical trial data and patient data in a database, analyzing the patient data in view of criteria established from the clinical trial data, and determining a dose for each cancer therapy/drug. A method of adjusting treatment of a cancer patient.